Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054215 | 1.00 | CA1 (0.47) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL29697165 | 1.00 | CA1 (0.47) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL9345489 | 1.00 | CA1 (0.47) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL19390430 | 1.00 | CA1 (0.47) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL14372163 | 1.00 | CA1 (0.47) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL14747283 | 1.00 | CA1 (0.47) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL14747281 | 1.00 | CA1 (0.47) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL9838648 | 1.00 | CA1 (0.47) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL6101469 | 1.00 | CA1 (0.47) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL15721071 | 0.95 | CA1 (0.46) | CA1CA2CA7CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1677822-B1 | 4'-THIONUCLEOSIDES AND OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-7939677-B2 | Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation | ISIS PHARMACEUTICALS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939677-B2 | Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation | ISIS PHARMACEUTICALS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7875733-B2 | Nucleosides; RNA interference; gene expression inhibition; for use in therapeutic, diagnostic, and research applications involving gene silencing | ISIS PHARMACEUTICALS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875733-B2 | Nucleosides; RNA interference; gene expression inhibition; for use in therapeutic, diagnostic, and research applications involving gene silencing | ISIS PHARMACEUTICALS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20100324277-A1 | OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100324277-A1 | OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-1677822-A4 | 4'-THIONUCLEOSIDES AND OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20060247222-A1 | Glycosidase inhibitors and methods of synthesizing same | SIMON FRASER UNIVERSITY (CA) | 2006-11-02 | — | — | US | disclosed |
| WO-2005027962-A9 | 4’-THIONUCLEOSIDES AND OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 2006-08-10 | — | — | WO | disclosed |
| EP-1677822-A2 | 4'-THIONUCLEOSIDES AND OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050130923-A1 | Nucleosides; RNA interference; gene expression inhibition; for use in therapeutic, diagnostic, and research applications involving gene silencing | IONIS PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005027962-A1 | 4’-THIONUCLEOSIDES AND OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324277-A1 | OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION | SNRPE, NSUN3, NSUN2 | CA1 4829/4885CA2 4863/4885CA7 4743/4885 |
| US-20050130923-A1 | Nucleosides; RNA interference; gene expression inhibition; for use in therapeutic, diagnostic, and research applications involving gene silencing | NSUN2, SNRPE, SNRPA | CA1 4866/4885CA2 4872/4885CA7 4768/4885 |
| US-20060247222-A1 | Glycosidase inhibitors and methods of synthesizing same | STS, SCLY, MGAM | CA1 148/4885CA2 216/4885CA7 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.